Abstract: Objective To demonstrate qualitatively the efficacy and safety of tobramycin-dexamethasone eye drops to control ocular inflammation after cataract surgery. Design Prospective case series. Participants 238 age-related cataract patients (284 eyes) undergoing ultrasonic emulsification cataract extraction with intraocular lens implantation. Methods  Tobramycin-dexamethasone eye drops (TobraDex?誖) were instilled for one month postoperatively. Intraocular pressure, redness analysis with keratography and R-scan software, aqueous flare measurement with Kowa FM600 Laser Flare Meter and foveal retinal thickness with Spectralis OCT were assessed at 1 day preoperatively, 1 day, 1 week and 1 month postoperatively. Main Outcome Measures Intraocular pressure, conjunctival hyperemia and ciliary hyperemia, aqueous flare and foveal retinal thickness. Results 1.75% of a total of 284 eyes reported glucocorticoid-induced ocular hypertension while receiving to bramycin-dexamethasone eye drops postoperatively. Conjunctival hyperemia and ciliary hyperemia were obviously alleviated after local application of tobramycin-dexamethasone eye drops for 1 week and 1 month compared with 1 day postoperatively（χ2=315.35, 190.69, P=0.000）, and they were similar to the preoperative level after 1 month. Degree of aqueous flare, 1 week postoperatively was (13.3±7.5) pc/ms, (8.1±5.2) pc/ms after 1 month, is reduced obviously compared with 1 day postoperatively (18.2±9.8) pc/ms (P=0.000). No significant difference was found in foveal retinal thickness which is (254.1±28.4) μm at 1 month postoperation and (249.2±17.8) μm preoperatively. Conclusion Through prospective quantitative detection of fovea thickness, ocular hyperemia, and aqueous protein concentration, the results show TobraDex?誖 instilled for one month to control and prove post-surgical ocular inflammation after emulsification cataract extraction is safe and effective. (Ophthalmol CHN, 2015, 24: 51-55)

Key words:  glucocorticoid, ultrasonic emulsification cataract extraction